Ligand And Agenus Enter Into $100M Royalty Financing Agreement
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals and Agenus Inc. have entered into a $100M royalty financing agreement to support the clinical development, Phase 3 trial, and launch readiness activities for botensilimab and balstilimab (BOT/BAL). Ligand will receive royalties and milestone payments on six Agenus-partnered programs and on future global net sales of BOT/BAL. The deal also includes an option for up to an additional $125 million in capital through syndication.
May 07, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agenus Inc. secures a $100M royalty financing agreement with Ligand Pharmaceuticals for the development and launch of BOT/BAL, with an option for up to $125M more in capital.
This financing agreement provides Agenus with crucial funding for the development, trial, and launch of BOT/BAL, which could significantly advance its product pipeline and future revenue potential. The option for additional capital also supports its financial stability and growth prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Ligand Pharmaceuticals enters a $100M royalty financing agreement with Agenus for BOT/BAL development, with potential for additional capital and future royalties.
The agreement provides Ligand with a significant capital infusion and future revenue streams through royalties and milestone payments, which is likely to be viewed positively by investors. The potential for additional capital through syndication further enhances its financial flexibility.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90